InsidersTradesSigma
基于 5 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Browse the complete record of transactions filed by Shenouda Maged. Director active across 2 companies, notably Relmada Therapeutics, INC.. Cumulatively, 8 disclosures have been logged. Breakdown: 7 buys · 0 sell. Total volume traded: €1.8m. History available since 29 January 2024. The latest transaction was filed on 9 September 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 条申报中的 8 条
Shenouda Maged is a declarant linked to Relmada Therapeutics, INC. as Chief Financial Officer and to Protea Biosciences Group, Inc. as Director. Across 6 filings in total, the 6 sampled filings cover the period from 2016-01-07 to 2025-12-16 and show only acquisitions, with buy volume of EUR 1073728 and no sales reported.